GlassScriptPhysician profile
Seban Liu
NPI 1174904304
$10,115.90
in general payments reported to CMS, 2019-2025
30 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2021: $344 · 2022: $2,644 · 2023: $2,087 · 2024: $1,734 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,153 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,153.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,088.43 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Boston Scientific Corporation | $869.62 | 2019-2023 | Watchman Access System |
| Amgen INC. | $791.54 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $747.65 | 2022-2025 | |
| Medtronic, INC. | $629.71 | 2021-2025 | Hawkone, Symplicity G3, Onyx Frontier |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.20 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $601.34 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Preventric Diagnostics, INC. | $539.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $508.12 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $494.96 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $465.76 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $417.59 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $416.41 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $378.44 | 2022-2025 | Amvuttra, Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $283.09 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $245.12 | 2022-2025 | Nexletol |
| United Therapeutics Corporation | $145.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $145.39 | 2022-2025 | Evkeeza, Praluent |
| Lexicon Pharmaceuticals, INC. | $139.34 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $132.57 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $130.45 | 2023-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $87.08 | 2023-2025 | |
| Vifor Pharma, INC. | $58.51 | 2022-2023 | Veltassa |
| Abbott Laboratories | $54.13 | 2022-2025 | Mitraclip |
| Cook Medical LLC | $33.84 | 2024 | Zenith Spiral-Z |
| Kiniksa Pharmaceuticals International, Plc | $25.19 | 2024 | Arcalyst |
| Medicomp INC | $23.02 | 2025 | Telepatch Cardiac Monitor |
| Atricure, INC. | $21.32 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.16 | 2024 | |
| Chiesi USA, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seban Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.